H3.3 ctl peptides and uses thereof

Patent metadata

Field	Value
Publication number	US-2025090636-A1
Application number	US-202418667792-A
Country	US
Kind code	A1
Filing date	May 17, 2024
Priority date	May 5, 2015
Publication date	Mar 20, 2025
Grant date	—

Abstract

Peptides that generate an immune response to glioma-related H3.3 proteins and methods of their use are provided.

First claim

1 - 57 . (canceled)

58 . A polynucleotide sequence encoding TCR or a fragment thereof, which binds to a peptide/major histocompatibility complex (MHC) complex, wherein the TCR or the fragment thereof binds to a histone H3 variant H3.3 peptide, and wherein the TCR or fragment thereof comprises:
(a) a TCR alpha chain or fragment thereof comprising complementarity determining regions (CDRs) 1, 2, and 3 comprising SEQ ID NOs: 12, 13, and 14, respectively; and (b) a TCR beta chain or fragment thereof comprising CDRs 1, 2, and 3 comprising SEQ ID NOs: 15, 16, and 17, respectively.

59 . The polynucleotide sequence according to claim 58 , wherein the TCR alpha chain comprises the amino acid sequence set forth in SEQ ID NO: 8, and the TCR beta chain comprises the amino acid sequence set forth in SEQ ID NO: 10.

60 . The polynucleotide sequence according to claim 58 , wherein the polynucleotide sequence comprises one or more heterologous sequences.

61 . The polynucleotide sequence according to claim 60 , wherein the one or more heterologous sequences is a promoter.

62 . The polynucleotide sequence according to claim 60 , wherein the one or more heterologous sequences encodes a self-cleaving peptide.

63 . The polynucleotide sequence according to claim 62 , wherein the self-cleaving peptide is a porcine teschovirus-1 2A (P2A) peptide.

64 . A vector comprising the polynucleotide sequence according to claim 58 .

65 . The vector according to claim 64 , wherein the vector is a viral vector.

66 . The vector according to claim 65 , wherein the viral vector is a lentiviral vector.

68 . A composition comprising the vector according to claim 64 .

69 . The polynucleotide sequence according to claim 58 , wherein the peptide in the peptide/MHC complex comprises the amino acid sequence (R/A) MSAP (S/A) TGGV (SEQ ID NO: 1).

70 . The polynucleotide sequence according to claim 69 , wherein the peptide in the peptide/MHC complex consists of 10-12 amino acids.

71 . The polynucleotide sequence according to claim 70 , wherein the amino acid sequence is RMSAPSTGGV (SEQ ID NO: 2).

Assignees

• Univ California

Inventors

• Okada Hideho
• Hou Yafei

Classifications

• A61K40/414

  Nervous system antigens · CPC title

• A61K40/32

  T-cell receptors [TCR] · CPC title

• A61K40/11

  T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells · CPC title

• A61K2239/47

  Brain; Nervous system · CPC title

• A61K2239/31

  characterized by the route of administration · CPC title